Search Medical Condition
Please enter condition
Please choose location

Chermside, Australia Clinical Trials

A listing of Chermside, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (100) clinical trials

5 Year Observation of Patients With PORTICO Valves

Further assess the performance and safety profile of the commercially available Portico Valve implanted, using the Delivery System and the Loading System, in patients with severe symptomatic aortic stenosis.

Phase N/A

0.0 miles

Learn More »

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive Metastatic Medullary Thyroid Cancer

The objective of this study is to evaluate the efficacy and safety of oral cabozantinib at a 60 mg dose compared with a 140 mg dose in subjects with progressive, metastatic MTC. It will test if the lower dose results in similar progression free survival (PFS) and overall response rate ...

Phase

0.0 miles

Learn More »

Nintedanib (BIBF 1120) in Mesothelioma

This is a phase II/III confirmatory study designed to evaluate the safety and efficacy of nintedanib (BIBF 1120) in combination + (pemetrexed / cisplatin) followed by nintedanib (BIBF 1120) versus placebo + pemetrexed / cisplatin followed by placebo for the treatment of patients with unresectable malignant pleural mesothelioma.

Phase

0.0 miles

Learn More »

Expanded Clinical Study of the Tendyne Mitral Valve System

The purpose of this study is to generate initial insights into the safety and performance of the Tendyne Mitral Valve System. The study includes adult patients with symptomatic mitral regurgitation who are not suitable candidates for conventional mitral valve repair or replacement. The study will include up to 110 subjects ...

Phase N/A

0.0 miles

Learn More »

A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis Homozygous for the F508del CFTR Mutation

The primary purpose of study is to evaluate the treatment effect of VX-661 in combination with ivacaftor (VX-661/ivacaftor) on chest imaging endpoints using low-dose computed tomography (LDCT) at Week 72, and to evaluate the safety of VX-661/ivacaftor through Week 72

Phase

0.0 miles

Learn More »

Absorb IV Randomized Controlled Trial

ABSORB IV: A. Primary Objective: - To evaluate 1-year clinical outcomes of the Absorb BVS compared to XIENCE in the treatment of subjects with ischemic heart disease caused by up to three de novo native coronary artery lesions in a maximum of two epicardial vessels, with a maximum of two ...

Phase N/A

0.37 miles

Learn More »

The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study

The purpose of this study is to assess the safety and clinical outcomes of the Edwards PASCAL Transcatheter Mitral Valve Repair (TMVr) System. This is a multi-center, multi-national, prospective, single arm, safety and clinical outcomes study.

Phase N/A

0.37 miles

Learn More »

ABSORB III Randomized Controlled Trial (RCT)

ABSORB III RCT: A. Primary Objective: The pivotal trial to support the US pre-market approval (PMA) of Absorb BVS. ABSORB III will evaluate the safety and effectiveness of the Absorb BVS System compared to the XIENCE in the treatment of subjects, including those with diabetes mellitus, with ischemic heart disease ...

Phase N/A

1.5 miles

Learn More »

A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)

The main purpose of this study is to compare maintenance treatment with avelumab plus best supportive care (BSC) with BSC alone, to determine if avelumab has an effect on survival in patients with locally advanced or metastatic urothelial cancer that did not worsen during or following completion of first-line chemotherapy.

Phase

1.54 miles

Learn More »

A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease

The purpose of this study is to evaluate the efficacy and safety of pirfenidone in participants with fibrosing interstitial lung disease (ILD) who cannot be classified with moderate or high confidence into any other category of fibrosing ILD by multidisciplinary team (MDT) review ("unclassifiable" ILD).

Phase

2.5 miles

Learn More »